This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Rexahn: Holes Galore in Serdaxin Data

If Rexahn had meant to study Serdaxin in patients with mild, moderate and severe depression, wouldn't the company have enrolled more patients in the former two categories? By inference, patients with mild and moderate depression only make up 31% of the study. And since Rexahn doesn't tell us anything about Serdaxin's performance in mild and moderate depressed patients I'm assuming the drug had no positive effect there. Rexahn also fails to disclose anything about the overall results of the study, which is odd.

The red flags identified in the first paragraph are multiplying. This subgroup analysis appears to be a data-mining expedition. Rexahn doesn't tell us anything about how patients with severe depression were defined clinically, which introduces bias, especially if this subgroup was identified after the company had all the Serdaxin data in hand.

More trouble. Rexahn appears to be subgrouping its subgroup. Notice that only 14 patients labeled with severe depression were treated with 5 mg of Serdaxin. But Rexahn told us that 53 patients in the study had severe depression. What happened to these missing patients?

I assume some of the missing severely depressed patients were assigned to the 14-patient placebo arm, but the others?

Let's go back to the first paragraph, which told us that the study was dose ranging. That means some patient with severe depression -- the "positive subgroup" -- must have been treated with higher or lower doses of Serdaxin.

Let's leave the Rexahn press release for a moment to see if we can find out anything about the other Serdaxin doses tested in this phase II study. Sure enough, the study is listed on the government's ClinicalTrials.gov website. Aha! Rexahn also assigned patients to receive treatment with 10 mg and 15 mg doses of Serdaxi.

Rexahn tells us that 5 mg dose of Serdaxin worked, but doesn't say anything about the two higher doses. That's not an encouraging sign. After all, if patients responded to the lowest 5 mg dose, why wouldn't they also respond, perhaps even better, to higher doses? That's called a dose response and is fairly common - and a positive indicator of efficacy -- in studies such as this.

So, in two paragraphs, we've gone from "compelling" evidence of Serdaxin's efficacy in depression to a retrospective analysis consisting of a subgroup (the low, 5 mg Serdaxin dose) of a subgroup (severely depressed patients .)

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
RNN $0.79 -1.30%
TRGT $2.64 0.38%
AAPL $129.08 0.48%
FB $79.74 0.98%
GOOG $571.00 2.30%

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs